Pharmaceutical Executive February 2016

February 2016 | Volume 36, Issue 2
From the Editor
William Looney identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive February 2016 issue in an interactive PDF format.
18 February, 2016.
Patent litigator Traci Medford-Rosow's story challenges the idea that the route to the top, as Pfizer’s SVP and chief IP counsel, is paved by right background and connections.
Canada’s Rx&D recently changed its name—with a mission of bridging the many points of collaboration that drive the process of modern drugs, from discovery to market. William Looney reports.
More oversight of regulatory programs and policies planned by GOP critics of the agency. Jill Wechsler reports.
Defending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.
What the drug industry stands to gain — or lose — from the unthinkable: Britain departing the European Union.
Emerging country market-access experts from McKinsey & Co. sit down with Pharm Exec to discuss next-level strategies needed to build sustainable local businesses that maximize patient access to the product portfolio.
An advocate of supply chain business system automation offers a six-pronged approach to adapting to a new age of mounting regulation and customer expectations.
Pharm Exec interviews Subhanu Saxena, CEO of India pharma giant Cipla, who discusses the longtime emerging market champion’s strategic plans to raise its geographic profile and secure the company’s future in the US.
Special Sponsored Section
By Pharmaceutical Executive Editors
In tandem with South Africa’s institutional advancements, driven by sweeping social and macroeconomic reforms, the pharma industry in the region is capitalizing on its core fundamentals: rising consumer disposable income, a positive demographic profile linked to an aging population, and a diverse disease burden requiring novel cures and treatments.
lorem ipsum